General Information
Drug ID
DR00170
Drug Name
Epirubicin
Synonyms
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin; Ebewe (TN); Ellence; Ellence (TN); Epi-DX; Epiadriamycin; Epidoxorubicin; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina; Epirubicina [INN-Spanish]; Epirubicina [Spanish]; Epirubicine; Epirubicine [French]; Epirubicine [INN-French]; Epirubicinum; Epirubicinum [INN-Latin]; Epirubicinum [Latin]; Farmorubicin (TN); IMI 28; Pharmorubicin (TN); Pharmorubicin Pfs; Pidorubicin; Pidorubicina; Pidorubicina [INN-Spanish]; Pidorubicine; Pidorubicine [INN-French]; Pidorubicinum; Pidorubicinum [INN-Latin]; Ridorubicin; WP 697
Drug Type
Small molecular drug
Indication Node-positive breast cancer [ICD11: 2C60-2C6Z] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C27H29NO11
Canonical SMILES
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
InChI
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
InChIKey
AOJJSUZBOXZQNB-VTZDEGQISA-N
CAS Number
CAS 56420-45-2
Pharmaceutical Properties Molecular Weight 543.5 Topological Polar Surface Area 206
Heavy Atom Count 39 Rotatable Bond Count 5
Hydrogen Bond Donor Count 6 Hydrogen Bond Acceptor Count 12
XLogP
1.3
PubChem CID
41867
PubChem SID
103164726 , 104338146 , 117597720 , 123080197 , 126686290 , 127301368 , 127301369 , 127301370 , 127301371 , 127301372 , 127301373 , 127301374 , 127301375 , 127301376 , 127301377 , 127301378 , 127301379 , 127301380 , 127301381 , 127301382 , 127301383 , 127301384 , 127301385 , 127301386 , 127301387 , 127301388 , 13409 , 14716206 , 14812446 , 14837077 , 24769893 , 26704252 , 26710264 , 34707467 , 46507282 , 46530809 , 48415946 , 49995002 , 50070726 , 53787927 , 56311421 , 56313206 , 56313988 , 57288587 , 57288773 , 57312617 , 77126435 , 793944 , 8177324 , 96024597
ChEBI ID
ChEBI:47898
TTD Drug ID
D0C9XJ
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [2]
P-GP Transporter Info P-glycoprotein 1 Substrate [2]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MRP1 Transporter Info Km = 0.097 microM Human cervical cancer cell line (Hela)-MRP1 [3]
References
1 Epirubicin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
3 Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res. 2016 Mar;30(2):120-133.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.